Development of targeted therapies in IgG4-related disease
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Shingo Nakayamada und 1 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Grant-In-Aid for Scien-tific Research.
Abstract (Originalsprache)
IgG4-related disease (IgG4-RD) is a systemic disease characterized by high serum IgG4 levels, infiltration of lymphocytes and IgG4-positive plasma cells into affected tissues, and subsequent fibrosis, forming mass, nodular, and thickened lesions in organs. Although glucocorticoids (GCs) are the first-line treatment for IgG4-RD, the disease often relapses during dose reduction or after discontinuation of GC. Long-term treatment with GC is associated with adverse effects such as infection, osteoporosis, and atherosclerosis. Therefore, there is an urgent need to develop a treatment strategy that specifically addresses the pathogenesis of IgG4-RD. As immunocompetent cells and immune-related molecules involved in the pathogenesis of IgG4-RD are increasingly being identified, there is a growing demand for new molecular-targeted drugs that target them. In particular, favourable results have been reported for drugs that target B cells, such as anti-cluster of differentiation (CD)20 and anti-CD19 antibodies. In addition, clinical trials are underway for new therapeutic agents, such as anti-signalling lymphocytic activation molecule family 7 antibodies that target T cells and other cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Förderung
- Grant-In-Aid for Scien-tific Research
Zitieren
APA
Nakayamada, S., & Tanaka, Y. (2023). Development of targeted therapies in IgG4-related disease. Modern Rheumatology. https://doi.org/10.1093/mr/roac096
Vancouver
Nakayamada S, Tanaka Y. Development of targeted therapies in IgG4-related disease. Modern Rheumatology. 2023. doi:10.1093/mr/roac096
BibTeX
@article{Nakayamada2023,
author = {Nakayamada, Shingo and Tanaka, Yoshiya},
title = {Development of targeted therapies in IgG4-related disease},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac096}
}
EUVIMED